Navigation Links
AMDL Teleconference Available on at 5:00 p.m. EDT Today

TUSTIN, Calif., May 22 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), ( ), a world leader in specialty pharmaceuticals with operations in Shenzhen, Jiangxi and Jilin, China, announced today that it has made available the AMDL executive management comments from its Q1 2008 financial results conference call. The document can be accessed via AMDL's corporate website at Click on "Investor Relations" then "Recent News."

The posted conference call script outlines prepared remarks AMDL's executive management made covering the Company's financial results for the first quarter of FY2008 and the subsequent question and answers from shareholders.
Highlighted comments from AMDL's CEO Gary Dreher included:

-- We have responded to the U.S. FDA regarding requests for information on

our DR-70(TM) cancer test within the time period required;

-- AMDL's executive management team is committed to increasing shareholder

communications, including formally issuing corporate guidance;

-- We are focused on growing annual sales at a minimum rate of 100 percent

over the next three years.

-- 2007 sales were $15 million and we are on track to at least doubling

sales in 2008;

-- AMDL will leverage its land holdings in China (estimated to be worth

between $15-$21 million) to gain a new credit facility in place by Q3,


-- We plan to finance continued growth with debt and credit lines. We do

not plan to pursue the same type of 25 percent discounted equity

funding as we've done in previous rounds;

-- AMDL's anti-aging Goodnak product line is enjoying high growth demand

and we anticipate it will be exported to the US and Europe in the


-- AMDL's head of R&D Dr. Andrea Small-Howard has concluded that the HPV

Test Kit licensed by the Company for distribution in China, Hong Kong,

Taiwan, Singapore, Malaysia, Thailand, Cambodia and Vietnam has

numerous advantages over other test kits for HPV and can become a major

product for the Company.

About AMDL:

AMDL, Inc. is a global specialty pharmaceutical company. The company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at .

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

IR Contact: Mr. Paul Knopick

Direct: 949.707.5365

Voicemail: 714.505.4460

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
2. HMS Holdings Corp. Hosts Third Quarter 2007 Financial Teleconference and Presentation
3. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
4. Onyx Pharmaceuticals Announces Third Quarter 2007 Financial Results Teleconference and Webcast
5. Vermillion to Host Teleconference and Webcast to Discuss Third Quarter 2007 Financial Results on November 12 at 4:30 pm Eastern Time
6. World AIDS Day Teleconference for Media, Including Helen Epstein, Author of the Invisible Cure, and Beatrice Were, Ugandan Womens Rights Advocate
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. Interactive Teleconference on Inflammatory Bowel Disease for Patients, Caregivers, and Healthcare Professionals
9. American Pacific to Release Financial Results and Hold Fiscal 2008 First Quarter Investor Teleconference
10. Progen Investor Teleconference Dial In Details
11. HMS Holdings Corp. Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: